Literature DB >> 6341388

Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.

L Bartalena, C Marcocci, L Chiovato, M Laddaga, G Lepri, D Andreani, G Cavallacci, L Baschieri, A Pinchera.   

Abstract

The effects of different methods of treatment of Graves' ophthalmopathy were evaluated in a series of 48 patients. Thirty-six patients were given combined treatment with orbital cobalt irradiation and systemic 6 alpha-methylprednisolone (methylprednisolone). Included in this group were 12 of 24 consecutive patients who were randomly assigned to either combined therapy or systemic methylprednisolone alone. The degree of ocular involvement and responses to treatment were evaluated by numerical scoring (ophthalmopathy index) and clinical assessment. Of the 36 patients treated by combined therapy, 12 (33%) showed excellent responses, 14 (39%) showed good responses, 9 (25%) showed slight responses, and 1 (3%) had no response. Treatment was more effective for soft tissue involvement, newly developed ophthalmoplegia, and optic neuropathy, while proptosis and longstanding ophthalmoplegia were less responsive. There was an inverse relationship between the duration of ophthalmopathy and the efficacy of treatment, more favorable results being observed when symptoms had been present for less than 2 yr. Treatment with systemic methylprednisolone alone was also effective, but, in general, responses were less satisfactory; 4 of the 12 patients of this group (33%) had good responses, 6 (50%) had slight responses, and 2 (17%) had no response. The results obtained in the 24 patients randomly assigned to combined therapy or steroid treatment alone were compared by evaluating changes in the ophthalmopathy index. Mean initial ophthalmopathy indices (6.4 vs. 6.2, respectively) showed no significant differences between the 2 groups, whereas the mean decrease in the group receiving combined therapy (4.8) was significantly greater (P less than 0.05) than that in the other group (3.2). In conclusion, the present study indicates that both orbital cobalt irradiation combined with systemic methylprednisolone treatment and systemic methylprednisolone therapy alone are valuable methods of treatment for Graves' ophthalmopathy, but the combined therapy proved to be more effective.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6341388     DOI: 10.1210/jcem-56-6-1139

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

Review 1.  Does radiotherapy have a role in the management of thyroid orbitopathy? View 1.

Authors:  Kimberley P Cockerham; John S Kennerdell
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

Review 2.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

Review 3.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  [Drug therapy and radiotherapy in Graves' orbitopathy].

Authors:  F Beisse; W A Lagrèze; M Schmucker
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

5.  Somatostatin-receptor scintigraphy in Graves' orbitopathy.

Authors:  P T Postema; D J Kwekkeboom; P M van Hagen; E P Krenning
Journal:  Eur J Nucl Med       Date:  1996-06

Review 6.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

7.  More on smoking habits and Graves' ophthalmopathy.

Authors:  L Bartalena; E Martino; C Marcocci; F Bogazzi; M Panicucci; F Velluzzi; A Loviselli; A Pinchera
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

8.  Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.

Authors:  E Sisti; F Menconi; M Leo; M A Profilo; T Mautone; B Mazzi; R Rocchi; F Latrofa; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

Review 9.  The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.

Authors:  Yang Wang; Huifang Zhou; Xianqun Fan
Journal:  Front Med       Date:  2017-05-13       Impact factor: 4.592

10.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.